entertainment -WSS

entertainment

author：hotspot 2025-10-02 22:27:07 - browse：68

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： GOP inquiry over gain

focus

WSS

UnitedHealth wins $3.3 billion takeover of Amedisys

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Amid AI frenzy, a top HHS official's quest to create safeguards

ADA: All diabetes patients should be screened for liver condition

Eating disorder hotline's move to chatbot carried cost for volunteers

Male and female sex labels in research insufficient, scientists say

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amid AI frenzy, a top HHS official's quest to create safeguards

United colonoscopy coverage change 'may cost lives,' doctors say

Amid AI frenzy, a top HHS official's quest to create safeguards

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: CAR

Bright Health sells Medicare Advantage business to Molina

RaDonda Vaught links Vanderbilt hospital issues to patient death

BioMarin wins approval for gene therapy to treat hemophilia A

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

leisure time

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

As AI in medicine takes off, can 'human in the loop' prevent harm?

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Change Healthcare outage fallout shows need for new oversight

Why depression after traumatic brain injury is distinct

focus

entertainment

hotspot

hotspot